333 related articles for article (PubMed ID: 9732227)
1. Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients.
Katona C; Kralovánszky J; Rosta A; Pandi E; Fónyad G; Tóth K; Jeney A
Oncology; 1998; 55(5):468-74. PubMed ID: 9732227
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
3. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.
Di Paolo A; Danesi R; Falcone A; Cionini L; Vannozzi F; Masi G; Allegrini G; Mini E; Bocci G; Conte PF; Del Tacca M
Ann Oncol; 2001 Sep; 12(9):1301-6. PubMed ID: 11697844
[TBL] [Abstract][Full Text] [Related]
4. [Determination of dihydropyrimidine dehydrogenase in the prediction of toxic side effects of 5-fluorouracil].
Katona C; Rosta A; Tóth K; Fónyad G; Jeney A; Pandi E; Kralovánszky J
Orv Hetil; 1997 Jul; 138(29):1843-7. PubMed ID: 9280881
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
Raida M; Schwabe W; Häusler P; Van Kuilenburg AB; Van Gennip AH; Behnke D; Höffken K
Clin Cancer Res; 2001 Sep; 7(9):2832-9. PubMed ID: 11555601
[TBL] [Abstract][Full Text] [Related]
6. [Population study of dihydropyrimidine dehydrogenase in cancer patients].
Etienne MC; Milano G; Renée N; Lagrange JL; Dassonville O; Thyss A; Schneider M; François E; Fleming R; Demard F
Bull Cancer; 1995 Sep; 82(9):705-10. PubMed ID: 8535028
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of two fluorouracil administration regimens for colorectal cancer.
Matsusaka S; Yamasaki H; Kitayama Y; Okada T; Maeda S
Oncol Rep; 2003; 10(1):109-13. PubMed ID: 12469154
[TBL] [Abstract][Full Text] [Related]
8. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
9. Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU.
Isshi K; Sakuyama T; Gen T; Nakamura Y; Kuroda T; Katuyama T; Maekawa Y
Int J Clin Oncol; 2002 Dec; 7(6):335-42. PubMed ID: 12494248
[TBL] [Abstract][Full Text] [Related]
10. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
van Kuilenburg AB
Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
[TBL] [Abstract][Full Text] [Related]
11. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
Ogura K
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
[TBL] [Abstract][Full Text] [Related]
12. Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients.
Teh LK; Hamzah S; Hashim H; Bannur Z; Zakaria ZA; Hasbullani Z; Shia JK; Fijeraid H; Md Nor A; Zailani M; Ramasamy P; Ngow H; Sood S; Salleh MZ
Ther Drug Monit; 2013 Oct; 35(5):624-30. PubMed ID: 23942539
[TBL] [Abstract][Full Text] [Related]
13. Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated with response to 5-fluorouracil in human colorectal cancer.
Araki Y; Isomoto H; Shirouzu K
Kurume Med J; 2001; 48(2):93-8. PubMed ID: 11501504
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of clinical value of single nucleotide polymorphisms of dihydropyrimidine dehydrogenase gene to predict 5-fluorouracil toxicity in 60 colorectal cancer patients in China.
Zhang X; Sun B; Lu Z
Int J Med Sci; 2013; 10(7):894-902. PubMed ID: 23781135
[TBL] [Abstract][Full Text] [Related]
15. Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy.
Morrison GB; Bastian A; Dela Rosa T; Diasio RB; Takimoto CH
Oncol Nurs Forum; 1997; 24(1):83-8. PubMed ID: 9007910
[TBL] [Abstract][Full Text] [Related]
16. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation.
Fischel JL; Etienne MC; Spector T; Formento P; Renée N; Milano G
Clin Cancer Res; 1995 Sep; 1(9):991-6. PubMed ID: 9816071
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
Int J Cancer; 2002 Sep; 101(3):253-8. PubMed ID: 12209976
[TBL] [Abstract][Full Text] [Related]
18. Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis.
Ikeguchi M; Makino M; Kaibara N
Langenbecks Arch Surg; 2002 Oct; 387(5-6):240-5. PubMed ID: 12410361
[TBL] [Abstract][Full Text] [Related]
19. Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits.
Milano G; Etienne MC
Ther Drug Monit; 1996 Aug; 18(4):335-40. PubMed ID: 8857547
[TBL] [Abstract][Full Text] [Related]
20. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver.
Chazal M; Etienne MC; Renée N; Bourgeon A; Richelme H; Milano G
Clin Cancer Res; 1996 Mar; 2(3):507-10. PubMed ID: 9816197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
